Sun Pharmaceutical Industries Ltd.
-31.35 (-1.84%) Sun Pharma inks licensing agreement with Zydus Lifesciences for co-marketing of Desidustat
Date: 30-10-2023Sun Pharmaceutical Industries and Zydus Lifesciences have entered into a licensing agreement to co-market an innovative drug, Desidustat in India. Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease (CKD) in India.
Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to co-market the product in India. Sun Pharma will market the drug under the brand name RYTSTAT. Zydus launched the drug under the brand name Oxemia in 2022 and will continue to market it. Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.